Allogene Therapeutics (ALLO) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
3 May, 2026Executive summary
Focus for 2026 is on delivering key clinical milestones for cema-cel in ALPHA3 (large B-cell lymphoma) and ALLO-329 in RESOLUTION (autoimmune diseases), aiming to validate the allogeneic CAR T platform as scalable and accessible.
ALPHA3 is the first randomized study in lymphoma to test MRD-guided consolidation with allogeneic CAR T, targeting earlier intervention and broader access, especially in community settings.
ALLO-329 leverages dual CD19/CD70 targeting and Dagger technology to potentially reduce or eliminate traditional lymphodepletion in autoimmune indications.
ALLO-316 in RCC completed Phase 1b enrollment; partnering opportunities are being explored.
Financial highlights
Cash, cash equivalents, and investments totaled $258.3 million as of December 31, 2025.
Additional $23.7 million received in February 2026 from escrow related to arbitration; $20.7 million raised via ATM equity facility year-to-date.
R&D expenses for Q4 2025 were $28.6 million; full-year R&D expenses were $150.2 million.
G&A expenses for Q4 2025 were $13.8 million; full-year G&A expenses were $56.8 million.
Net loss for Q4 2025 was $38.8 million ($0.17/share); full-year net loss was $189.9 million ($0.87/share).
Outlook and guidance
Cash runway expected to last into Q1 2028, covering estimated completion of ALPHA3 enrollment.
2026 operating cash expense guidance is ~$150 million; GAAP operating expenses expected at ~$210 million, including ~$35 million in non-cash stock-based compensation.
Pivotal ALPHA3 data expected in April 2026; ALLO-329 proof of concept data anticipated in June 2026.
Latest events from Allogene Therapeutics
- Annual meeting to address director elections, executive pay, share increase, and auditor ratification.ALLO
Proxy filing1 May 2026 - Key votes include director elections, doubling authorized shares, and auditor ratification.ALLO
Proxy filing30 Apr 2026 - Key votes include director elections, executive pay, share increase, and auditor ratification.ALLO
Proxy filing20 Apr 2026 - Cema-cel achieved 58.3% MRD clearance and strong safety, supporting outpatient use in LBCL.ALLO
Study result20 Apr 2026 - Pivotal allogeneic CAR T programs target multi-billion dollar markets with key data in 2026.ALLO
Corporate presentation12 Mar 2026 - Key clinical milestones and manufacturing advances position allogeneic cell therapy for broad impact.ALLO
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - ALPHA3 aims to transform lymphoma care by targeting MRD-positive patients with cema-cel.ALLO
Citi’s 2026 Virtual Oncology Leadership Summit18 Feb 2026 - Allogeneic CAR T programs advance toward key 2025–2026 milestones with robust financial support.ALLO
Stifel 2024 Healthcare Conference3 Feb 2026 - Allogeneic cell therapy is poised for broad impact, with pivotal trials and scalable manufacturing underway.ALLO
Goldman Sachs Cell Therapy Day3 Feb 2026